FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

🤖 AI 摘要

The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT).

分析模型：rule-based-v3 · 07-09 06:59